Compare UHT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UHT | CTNM |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 550.7M |
| IPO Year | 1995 | 2024 |
| Metric | UHT | CTNM |
|---|---|---|
| Price | $40.72 | $13.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $43.00 | $19.00 |
| AVG Volume (30 Days) | 81.8K | ★ 368.7K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $99,190,000.00 | N/A |
| Revenue This Year | $2.12 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $51.57 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $35.26 | $8.60 |
| 52 Week High | $46.30 | $17.79 |
| Indicator | UHT | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 42.23 |
| Support Level | $39.63 | $13.23 |
| Resistance Level | $42.79 | $15.36 |
| Average True Range (ATR) | 0.77 | 0.84 |
| MACD | 0.01 | -0.31 |
| Stochastic Oscillator | 37.26 | 6.61 |
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.